Movement Alert｜Definium Therapeutics Rises 5.1% in Pre-Market Trading, DT120 Phase 3 Data and Capital Raise Continue to Fuel Momentum

Market Focus07-16

On July 16, Definium Therapeutics rose 5.1% in pre-market trading, trading at $48.0/share, with turnover of $62,900. The stock continues to rally as multiple positive catalysts sustain buying momentum.

On the news front, the company previously announced that its core candidate DT120 oral disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful superiority over placebo. Subsequently, Definium successfully completed an $805 million follow-on offering with underwriters fully exercising the overallotment option, with proceeds earmarked for DT120 commercialization preparation and pipeline advancement. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating. With the current share price still trading below the upgraded target, market buying pressure continues.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147939149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147939149","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Definium Therapeutics Rises 5.1% in Pre-Market Trading, DT120 Phase 3 Data and Capital Raise Continue to Fuel Momentum","media":"Market Focus","content":"<p><p>On July 16, Definium Therapeutics rose 5.1% in pre-market trading, trading at $48.0/share, with turnover of $62,900. The stock continues to rally as multiple positive catalysts sustain buying momentum.</p><p>On the news front, the company previously announced that its core candidate DT120 oral disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful superiority over placebo. Subsequently, Definium successfully completed an $805 million follow-on offering with underwriters fully exercising the overallotment option, with proceeds earmarked for DT120 commercialization preparation and pipeline advancement. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating. With the current share price still trading below the upgraded target, market buying pressure continues.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Definium Therapeutics Rises 5.1% in Pre-Market Trading, DT120 Phase 3 Data and Capital Raise Continue to Fuel Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Definium Therapeutics Rises 5.1% in Pre-Market Trading, DT120 Phase 3 Data and Capital Raise Continue to Fuel Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Definium Therapeutics rose 5.1% in pre-market trading, trading at $48.0/share, with turnover of $62,900. The stock continues to rally as multiple positive catalysts sustain buying momentum.</p><p>On the news front, the company previously announced that its core candidate DT120 oral disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful superiority over placebo. Subsequently, Definium successfully completed an $805 million follow-on offering with underwriters fully exercising the overallotment option, with proceeds earmarked for DT120 commercialization preparation and pipeline advancement. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating. With the current share price still trading below the upgraded target, market buying pressure continues.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"","article_id":"1147939149","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147939149","pubTimestamp":1784191651,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Definium Therapeutics rose 5.1% in pre-market trading, trading at $48.0/share, with turnover of $62,900. The stock continues to rally as multiple positive catalysts sustain buying...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics"},"translate_title":"走势警报|Definium Therapeutics 盘前交易上涨 5.1%，DT120 第三阶段数据和融资继续推动动力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1},"content_text":"On July 16, Definium Therapeutics rose 5.1% in pre-market trading, trading at $48.0/share, with turnover of $62,900. The stock continues to rally as multiple positive catalysts sustain buying momentum.On the news front, the company previously announced that its core candidate DT120 oral disintegrating tablet achieved positive topline results in the pivotal Phase 3 EMERGE study for major depressive disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful superiority over placebo. Subsequently, Definium successfully completed an $805 million follow-on offering with underwriters fully exercising the overallotment option, with proceeds earmarked for DT120 commercialization preparation and pipeline advancement. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating. With the current share price still trading below the upgraded target, market buying pressure continues.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147939149","isCrawlerRequest":true}